文献速递心脑血管急症复苏、休克与脓毒症

艾司洛尔在院前难治性心室颤动管理中的应用:系统评价与荟萃分析

Esmolol in the management of pre-hospital refractory ventricular fibrillation: A systematic review and meta-analysis.
PubMed 文献 · Am J Emerg Med · 2020-05-29
一句话结论系统评价与荟萃分析显示,艾司洛尔可能提高院前难治性室颤/无脉性室速患者的生存出院率、神经功能良好生存率及ROSC率,但证据确定性极低,疗效仍不明确。

该系统评价与荟萃分析检索MEDLINE、Embase、Scopus和Cochrane CENTRAL,纳入2项研究共66例院前难治性室颤/无脉性室速患者,其中22例(33.3%)接受艾司洛尔。与标准治疗相比,艾司洛尔可能提高生存出院率(RR 2.82,95%CI 1.01-7.93,p=0.05)、神经功能良好生存率(RR 3.44,95%CI 1.11-10.67,p=0.03)、ROSC率(RR 2.63,95%CI 1.37-5.07,p=0.004)和ICU/入院生存率(RR 2.63,95%CI 1.37-5.07,p=0.004),但所有结局证据质量均为极低(GRADE:Very low)。作者结论认为艾司洛尔对难治性室颤/无脉性室速的疗效仍不明确,试验序贯分析提示证据不确定,需进一步试验才能得出结论。

要点

  • 纳入2项研究共66例院前难治性室颤/无脉性室速患者,22例(33.3%)接受艾司洛尔,33.3%为接受艾司洛尔者占全部患者的比例。
  • 艾司洛尔组ROSC率较标准治疗组升高(RR 2.63,95%CI 1.37-5.07,p=0.004),但证据质量极低(GRADE:Very low)。
  • 艾司洛尔组生存出院率较标准治疗组升高(RR 2.82,95%CI 1.01-7.93,p=0.05),但证据质量极低(GRADE:Very low)。
  • 艾司洛尔组神经功能良好生存率较标准治疗组升高(RR 3.44,95%CI 1.11-10.67,p=0.03),但证据质量极低(GRADE:Very low)。
  • 作者结论认为艾司洛尔对院前难治性室颤/无脉性室速的疗效仍不明确,试验序贯分析提示证据不确定,需进一步试验。

适用人群与场景

  • 院前难治性心室颤动/无脉性心室心动过速(VF/pVT)患者。

研究设计与关键结果

  • 研究类型:系统评价与荟萃分析,检索MEDLINE、Embase、Scopus和Cochrane CENTRAL,共3253条唯一记录,最终纳入2项研究,共66例患者,其中33.3%(n=22)接受艾司洛尔。
  • 与标准治疗相比,艾司洛尔可能提高生存出院率(RR 2.82,95%CI 1.01-7.93,p=0.05)(GRADE:Very low)。
  • 与标准治疗相比,艾司洛尔可能提高神经功能良好生存率(RR 3.44,95%CI 1.11-10.67,p=0.03)(GRADE:Very low)。
  • 与标准治疗相比,艾司洛尔可能提高ROSC率(RR 2.63,95%CI 1.37-5.07,p=0.004)(GRADE:Very low)。
  • 与标准治疗相比,艾司洛尔可能提高ICU/入院生存率(RR 2.63,95%CI 1.37-5.07,p=0.004)(GRADE:Very low)。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析,纳入2项研究,采用ROBINS-I工具评估方法学质量,GRADE指南评估证据质量。
  • 所有结局证据质量均为极低(GRADE:Very low)。
  • 作者结论:艾司洛尔对难治性室颤/无脉性室速的疗效仍不明确;试验序贯分析(TSA)提示证据不确定,需进一步试验才能得出结论。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为艾司洛尔对院前难治性室颤/无脉性室速的疗效仍不明确,试验序贯分析提示证据不确定,需进一步试验才能得出结论。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Esmolol has been proposed as a viable adjunctive therapy for pre-hospital refractory ventricular fibrillation/pulseless ventricular tachycardia (VF/pVT).

OBJECTIVES: We performed a systematic review and meta-analysis to assess the effectiveness of esmolol on pre-hospital refractory VF/pVT, compared with standard of care.

METHODS: MEDLINE, Embase, Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched for eligible studies. Two investigators independently extracted relevant data and assessed the methodological quality of each included study using the ROBINS-I tool. The quality of evidence for summary estimates was assessed according to GRADE guidelines. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) for each outcome of interest were calculated.

RESULTS: The search yielded 3253 unique records, of which two studies were found to be in accordance with the research purpose, totaling 66 patients, of whom 33.3% (n = 22) received esmolol. Additional evidence was provided in the paper but was not relevant to the analysis and was therefore not included. Esmolol was likely associated with an increased rate of survival to discharge (RR 2.82, 95% CI 1.01-7.93, p = 0.05) (GRADE: Very low) and survival with favorable neurological outcome (RR 3.44, 95% CI 1.11-10.67, p = 0.03) (GRADE: Very low). Similar results were found for return of spontaneous circulation (ROSC) (RR 2.63, 95% CI 1.37-5.07, p = 0.004) (GRADE: Very low) and survival to intensive care unit (ICU)/hospital admission (RR 2.63, 95% CI 1.37-5.07, p = 0.004) (GRADE: Very low).

CONCLUSION: The effectiveness of esmolol for refractory VF/pVT remains unclear. Trial sequential analysis (TSA) indicates that the evidence is inconclusive and that further trials are required in order to reach a conclusion. Therefore, it is imperative to continue to accumulate evidence in order to obtain a higher level of scientific evidence.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Miraglia D, Miguel LA, Alonso W, et al. Esmolol in the management of pre-hospital refractory ventricular fibrillation: A systematic review and meta-analysis. Am J Emerg Med. 2020. PMID: 32777667. doi:10.1016/j.ajem.2020.05.083

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。